Massive Heart Wall Thickening in Kids with HCM Triples Sudden Death Risk
A multiregistry study of 587 pediatric HCM patients finds massive LVH dramatically raises arrhythmia and mortality risk, especially in young children.
Summary
A large international study examined children with hypertrophic cardiomyopathy (HCM) — a condition where the heart muscle becomes abnormally thick — focusing on those with extreme wall thickening. Researchers found that children with massive left ventricular hypertrophy were diagnosed younger, more often carried genetic mutations, and faced triple the risk of life-threatening arrhythmias and over three times the HCM-related mortality compared to peers without massive thickening. Notably, about one in four patients showed meaningful regression of wall thickness over time, suggesting the condition is not always progressive. These findings, drawn from two major international registries spanning over six decades, help clarify who is at highest risk and may inform decisions about implantable defibrillators and monitoring strategies in pediatric cardiology.
Detailed Summary
Hypertrophic cardiomyopathy (HCM) is the leading cause of sudden cardiac death in young people, and extreme left ventricular wall thickening — known as massive LVH — is one of its most feared features. Yet until now, the long-term natural history of massive LVH in children has been poorly understood, limiting clinicians' ability to counsel families and make risk-stratification decisions.
This multiregistry analysis pooled data from the SHaRe and IPHCC registries, encompassing 587 pediatric HCM patients from institutions across North America, Europe, Australia, and South America, with follow-up data spanning from 1960 to 2024. Massive LVH was defined as a maximum left ventricular wall thickness of 30 mm or more, or a z-score of +20 or higher, in patients under 18.
Of the 587 patients, 186 met criteria for massive LVH. These children were diagnosed significantly younger (median age 9.2 vs. 13.6 years) and more frequently carried sarcomeric gene variants (72% vs. 61%). Critically, massive LVH was associated with a 3.3-fold increase in HCM-related mortality, a 3.1-fold increase in major ventricular arrhythmia events, a 2.6-fold increase in major adverse cardiac events, and a 1.9-fold increase in heart failure events — all statistically significant and robust after adjustment for age and sex.
Serial imaging data revealed that while absolute wall thickness increased over time, z-scores remained stable, suggesting growth-relative thickening may plateau. Importantly, 22% of patients showed meaningful wall thickness regression of more than 5 mm, a clinically significant finding that challenges assumptions of inevitable progression.
These results have direct implications for ICD implantation decisions, genetic screening prioritization, and surveillance frequency in pediatric HCM. Caveats include registry-based design, potential selection bias toward higher-risk centers, and the summary being based on the abstract only.
Key Findings
- Massive LVH in pediatric HCM triples the risk of major ventricular arrhythmia (HR 3.1) and HCM-related mortality (HR 3.3).
- Children with massive LVH are diagnosed nearly 4.5 years earlier than peers without it (median age 9.2 vs. 13.6 years).
- Sarcomeric genetic variants are significantly more prevalent in massive LVH patients (72% vs. 61%).
- Nearly 1 in 4 patients (22%) showed meaningful wall thickness regression over time, challenging assumptions of inevitable progression.
- Z-score-based wall thickness remained stable despite absolute thickness increasing, suggesting growth-adjusted burden may plateau.
Methodology
Retrospective multiregistry analysis using SHaRe and IPHCC databases, covering 587 pediatric HCM patients from international centers with data spanning 1960–2024. Massive LVH was defined by absolute wall thickness ≥30 mm or z-score ≥+20. Time-to-event analyses used Cox proportional hazards models adjusted for sex and age at diagnosis.
Study Limitations
This summary is based on the abstract only, as the full text is not open access. Registry-based design introduces potential selection bias toward tertiary care centers with higher-risk patients. Retrospective data spanning six decades may reflect heterogeneous diagnostic and treatment practices across eras and institutions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.